Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Acino Holding AG's Total Stockholders Equity for the quarter that ended in Dec. 2013 was CHF334.2 Mil. Acino Holding AG's Total Assets for the quarter that ended in Dec. 2013 was CHF560.5 Mil.
Therefore, Acino Holding AG's Equity to Asset Ratio for the quarter that ended in Dec. 2013 was 0.60.
The historical rank and industry rank for Acino Holding AG's Equity-to-Asset or its related term are showing as below:
XSWX:ACIN'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.55 Med: 0.71 Max: 0.87
Current: 0.6
During the past 11 years, the highest Equity to Asset Ratio of Acino Holding AG was 0.87. The lowest was 0.55. And the median was 0.71.
XSWX:ACIN's Equity-to-Asset is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.59
vs XSWX:ACIN: 0.60
Acino Holding AG Equity-to-Asset Historical Data
The historical data trend for Acino Holding AG's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Acino Holding AG's Equity-to-Asset
For the Drug Manufacturers - General subindustry, Acino Holding AG's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acino Holding AG's Equity-to-Asset Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Acino Holding AG's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Acino Holding AG's Equity-to-Asset falls into.
Acino Holding AG Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Acino Holding AG's Equity to Asset Ratio for the fiscal year that ended in Dec. 2013 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acino Holding AG (XSWX:ACIN) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Acino Holding AG Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Acino Holding AG's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Acino Holding AG is a Switzerland-based company engaged in the pharmaceutical industry. The Company develops, manufactures, and markets pharmaceuticals in novel drug delivery forms internationally. It is divided into four segments Business to Consumer (BtC); Business to Business (BtB); Technology marketing (TM); and Production (Prod). The BtC segment comprises all direct marketing activities. Under the company's "Acino Switzerland" brand and, with the promise of Swiss quality, the company sells its products in emerging markets around the globe. This reporting segment includes the business purchased from Mepha/Cephalon in the Middle East, Africa, Latin America and Asia. The BtB segment comprises Acino's business with its internally developed products, for which the company also owns the intellectual property rights. Acino develops and produces high-quality medicines with proven active ingredients and modern drug delivery systems and grants licenses for them to leading pharmaceutical and generic pharmaceutical companies worldwide. The technology marketing segment comprises a broad spectrum of fully integrated contract services, including procurement, contract development, production and packaging for companies in the life sciences industry. On behalf of these customers, Acino develops a comprehensive product pipeline on the basis of its special technological know-how. This includes both new types of medicines as well as projects with innovative drug delivery systems for established active ingredients. The production segment is responsible for the manufacturing of products and the supplying of the other three segments, and generates turnover through the reimbursement of its services. The manufacturing costs of products are credited to the production segment at standard prices along with remuneration in the form of a mark-up for materials and production costs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XSWX:ACIN has been successfully added to your 